TZIANABOS ARTHUR 4

What Happened

• Arthur Tzianabos, Interim Executive Chair and director of Stoke Therapeutics (STOK), exercised stock options for 3,955 shares at an exercise price of $8.33 per share (total cost reported $32,945) and, on the same date, sold 4,355 shares in an open-market transaction for reported proceeds of $174,214. The sale was executed on March 10, 2026.

Key Details

• Transaction date: March 10, 2026.
• Option exercise: 3,955 shares exercised at $8.33 per share (reported cost $32,945).
• Open-market sale: 4,355 shares sold at a weighted average price of $40.00 (range $40.00–$40.095), total proceeds reported $174,214.
• Footnotes: sale executed pursuant to a Rule 10b5-1 trading plan adopted August 15, 2025 (F1); reported sale price is a weighted average with prices in the $40.00–$40.095 range (F2); the option became fully vested and exercisable October 6, 2025 (F3).
• Shares owned after the transaction: not specified in the Form 4 filing.
• Filing: Form 4 filed March 12, 2026 reporting the March 10 transactions (no late filing indicated).

Context

• This filing shows an option exercise followed by an open-market sale. The exercise (paying ~$32.9K to acquire 3,955 shares) and the separate sale (proceeds of ~$174.2K) were reported the same day; the filing also includes a derivative disposition entry related to the exercised options. The sale was made under a pre-established 10b5-1 plan, which typically schedules trades in advance and can be routine.